Table 1. Baseline characteristics of study participants (n = 239).
| Characteristics | Categories | Frequency (%) |
|---|---|---|
| Gender | Male | 82 (34.3) |
| Female | 157 (65.7) | |
| Median age (years) | 33 (Interquartile range, IQR: 28–40) | |
| ART-experienced: | 31 (IQR: 29–40) | |
| ART-naïve: | 33 (IQR: 28–41) | |
| Age groups (years) | 19–29 | 75 (31.4) |
| 30–40 | 105 (43.9) | |
| > 40 | 59 (24.7) | |
| ART status | Treated | 70 (29.3) |
| Naive | 169 (70.7) | |
| Regimen type | Nevirapine-based (n = 44) | |
| d4T/3TC/NVP | 36 (51.4) | |
| AZT/3TC/NVP | 8 (11.4) | |
| Efavirenz-based (n = 26) | ||
| AZT/3TC/EFV | 17 (24.3) | |
| d4T/3TC/EFV | 9 (12.9) | |
| Median duration of ART: | 10.5 months (IQR: 4.0–17.3 months) | |
| Median CD4 (cells/μl): | 353.5 (IQR:145–471) | |
| ART-Experienced | 240 (IQR: 145–410) | |
| ART-Naïve | 405 (IQR: 146–546) | |
| Median Log10 viral load (copies/ml): | 4.89 (IQR: 3.91–5.55) | |
| ART-Experienced | 3.53 (IQR: 2.98–4.07) | |
| Art-Naïve | 5.20 (IQR: 4.67–5.72) | |
AZT-Zidovudine, 3TC-Lamivudine, NVP-Nevirapine, 4dT-Stavudine, EFV-Efavirenz